<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="6492">
  <stage>Registered</stage>
  <submitdate>13/10/2016</submitdate>
  <approvaldate>13/10/2016</approvaldate>
  <nctid>NCT02996500</nctid>
  <trial_identification>
    <studytitle>Safety and Efficacy of Pf-06650833 In Subjects With Rheumatoid Arthritis, With An Inadequate Response To Methotrexate</studytitle>
    <scientifictitle>A 12 Week Randomized, Double-blind, Double Dummy, Parallel Group, Active And Placebo-controlled, Multicenter Study To Assess The Efficacy And Safety Profile Of Pf-06650833 In Subjects With Active Rheumatoid Arthritis With An Inadequate Response To Methotrexate</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>2016-002337-30</secondaryid>
    <secondaryid>B7921005</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Rheumatoid Arthritis</healthcondition>
    <conditioncode>
      <conditioncode1>Musculoskeletal</conditioncode1>
      <conditioncode2>Osteoarthritis</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Inflammatory and Immune System</conditioncode1>
      <conditioncode2>Rheumatoid arthritis</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - PF-06650833
Treatment: drugs - Placebo
Treatment: drugs - Tofacitinib

Experimental: Arm 1: 20 mg QD - PF-06650833 , 20 mg QD

Experimental: Arm 2: 60 mg QD - PF-06650833, 60 mg QD

Experimental: Arm 3: 200 mg QD - Pf-06650833, 200 mg QD

Experimental: Arm 4: 400 mg QD - PF-06650833, 400 mg QD

Placebo Comparator: Placebo - Placebo, 0 mg BID

Active Comparator: Arm 5: Tofacitinib - Tofacitinib 5 mg BID


Treatment: drugs: PF-06650833
Investigational

Treatment: drugs: Placebo
Placebo

Treatment: drugs: Tofacitinib
Investigational

</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Change from baseline in the Simplified Disease Activity Index (SDAI) at Week 12</outcome>
      <timepoint>Baseline and 12 weeks</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Change from baseline in SDAI</outcome>
      <timepoint>Baseline, 4 and 8 weeks</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>SDAI low disease activity score (LDAS)</outcome>
      <timepoint>Baseline, 4, 8 and 12 weeks</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>DAS28 LDAS</outcome>
      <timepoint>Baseline, 4, 8 and 12 weeks</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Change from baseline DAS28-3</outcome>
      <timepoint>Baseline, 4, 8 and 12 weeks</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>ACR 20 responder rates</outcome>
      <timepoint>Baseline, 4, 8 and 12 weeks</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Change from baseline in the Tender/Painful and Swollen Joint Counts</outcome>
      <timepoint>Baseline, 4, 8 and 12 weeks</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Change from baseline in high sensitivity C-reactive protein (hsCRP)</outcome>
      <timepoint>Baseline, 4, 8 and 12 weeks</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Change from baseline in the Physician's Global Assessment of Arthritis (PhGA)</outcome>
      <timepoint>Baseline, 4, 8 and 12 weeks</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Change from baseline in the Patient's Assessment of Arthritis Pain (PAAP) VAS</outcome>
      <timepoint>Baseline, 4, 8 and 12</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Change from baseline in Patient Global Assessment of Arthritis (PtGA) VAS</outcome>
      <timepoint>Baseline, 4, 8 and 12 weeks</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Change from baseline in the HAQ-DI</outcome>
      <timepoint>Baseline, 4, 8 and 12 weeks</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Change from baseline in the SF 36v.2 (acute) 8 Domain scores</outcome>
      <timepoint>Baseline and 12 weeks</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Change from baseline in the EQ-5D 3L score</outcome>
      <timepoint>Baseline and 12 weeks</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Change from baseline in the FACIT-F total score</outcome>
      <timepoint>Baseline and 12 weeks</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Safety and tolerability of PF 06650833: vital signs (blood pressure, pulse, and temperature), laboratory tests, Adverse Events (AEs) and Serious Adverse Events (SAEs)</outcome>
      <timepoint>Baseline, 1, 4, 6 , 8, 10, 12, 14 and 16 weeks</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Urinalysis including urine microscopy.</outcome>
      <timepoint>Baseline, 1, 4, 6, 8, 10, 12, 14 and 16 weeks</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>12 lead ECG</outcome>
      <timepoint>Baseline, 1, 12 and 16 weeks</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>DAS-28 remission rate</outcome>
      <timepoint>4, 8 and 12 weeks</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>SDAI remission rate</outcome>
      <timepoint>4, 8, and 12 weeks</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Change from baseline DAS28 3 (CRP)</outcome>
      <timepoint>Baseline, 4,8 and 12</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Change from baseline DAS28 -4 (ESR)</outcome>
      <timepoint>Baseline, 4, 8 and 12</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Change from baseline DAS28 4 (CRP)</outcome>
      <timepoint>Baseline, 4, 8 and 12</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>ACR 50responder rates</outcome>
      <timepoint>Baseline, 4, 8 and 12</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>ACR 70 responder rates</outcome>
      <timepoint>Baseline, 4, 8 and 12</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Change from baseline in Physical Component Score (PCS)</outcome>
      <timepoint>Baseline and 12 weeks</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Change from baseline in Mental component score (MCS)</outcome>
      <timepoint>Baseline and 12 weeks</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>1. Male and female (including WOCBP) subjects between the ages of 18 and 75 years,
             inclusive.

          2. Diagnosis of RA and meeting the 2010 American College of Rheumatology (ACR)/European
             League Against Rheumatism (EULAR) classification criteria for RA with a Total Score
             =6/10.

          3. The subject has active disease at both Screening and Baseline, as defined by both:

               -  6 joints tender or painful on motion, AND

               -  6 joints swollen; and fulfills 1 of the following 2 criteria at Screening:

               -  High sensitivity C reactive protein (hsCRP) &gt;7 mg/L at screening

               -  Erythrocyte sedimentation rate (ESR) (Westergren method) &gt;28 mm/hr;

          4. Meets Class I, II or III of the ACR 1991 Revised Criteria for Global Functional Status
             in RA.

          5. Subjects must be ACPA positive between screening and randomization.

          6. Subjects must have been taking oral MTX for at least 3 months at an adequate dose to
             determine that the subject had an inadequate response to MTX

          7. Up to 50 % of subjects may have received one (and only one) approved TNF-inhibiting
             biologic agent administered that was inadequately effective and/or not tolerated. The
             anti-TNF biologic could also have been discontinued due to lack of continued access.</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>75</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>1. Subjects with a known immunodeficiency disorder or a first degree relative with a
             hereditary immunodeficiency.

          2. Subjects with any of the following infections or infections history:

               1. Any infection requiring treatment within 2 weeks prior to screening (Visit 1).

               2. Any infection requiring hospitalization, parenteral antimicrobial therapy within
                  60 days, or as otherwise judged to be an opportunistic infection or clinically
                  significant by the investigator, within the past 6 months.

               3. Infected joint prosthesis at any time with the prosthesis still in situ.

               4. Recurrent (more than one episode) herpes zoster or disseminated (a single
                  episode) herpes zoster or disseminated (a single episode) herpes simplex.

               5. Subjects will be screened for HIV. Subjects who test positive for HIV will be
                  excluded from the study.

               6. Subjects will be screened for hepatitis B virus infection and will be excluded if
                  positive for hepatitis B surface antigen (HBsAg). Subjects with HBsAg negative
                  testing but who test positive for hepatitis B core antibody (HBcAb) must have
                  further testing for hepatitis B surface antibody (HBsAb). If HBsAb is negative,
                  the subject will be excluded from the study.

               7. Subjects with clinically significant active hepatic disease or hepatic impairment
                  by laboratory assessment.

               8. Subjects will be screened for hepatitis C virus (HCV Ab). Subjects with positive
                  HCV Ab tests will be reflex tested for HCV ribonucleic acid (HCV RNA). Only
                  subjects with negative HCV Ab or HCV RNA will be allowed to enroll in the study.

          3. Evidence of active or latent, untreated or inadequately treated infection with
             Mycobacterium tuberculosis (TB)

          4. Pre-existing chronic autoimmune disease.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1>The people receiving the treatment/s</masking1>
    <masking2 />
    <masking3>The people assessing the outcomes</masking3>
    <masking4>The people analysing the results/data</masking4>
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 2</phase>
    <anticipatedstartdate />
    <actualstartdate>10/11/2016</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize>230</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Recruiting</recruitmentstatus>
    <anticipatedlastvisitdate>2/10/2018</anticipatedlastvisitdate>
    <actuallastvisitdate />
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>ACT,NSW</recruitmentstate>
    <hospital>Canberra Hospital - Garran</hospital>
    <hospital>Genesis Research Services - Broadmeadow</hospital>
    <postcode>2605 - Garran</postcode>
    <postcode>2292 - Broadmeadow</postcode>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Alabama</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Arizona</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>California</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Florida</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Georgia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Kentucky</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Louisiana</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Tennessee</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Texas</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Bosnia and Herzegovina</country>
      <state>Kanton Sarajevo</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Bosnia and Herzegovina</country>
      <state>Republika Srpska</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Bulgaria</country>
      <state>Plovdiv</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Bulgaria</country>
      <state>Sofia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Croatia</country>
      <state>Grad Zagreb</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Croatia</country>
      <state>Zagreb</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Czechia</country>
      <state>Brno</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Czechia</country>
      <state>Praha</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Czechia</country>
      <state>Uherske Hradiste</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Georgia</country>
      <state>Tbilisi</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Georgia</country>
      <state>Telavi</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Frankfurt</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Nienburg</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Püttlingen</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Hungary</country>
      <state>Budapest</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Hungary</country>
      <state>Kistarcsa</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Hungary</country>
      <state>Miskolc</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Hungary</country>
      <state>Szeged</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Hungary</country>
      <state>Szentes</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Hungary</country>
      <state>Veszprem</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Korea, Republic of</country>
      <state>Daegu</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Korea, Republic of</country>
      <state>Seoul</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Mexico</country>
      <state>Morelos</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Mexico</country>
      <state>Yucatan</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Poland</country>
      <state>Bytom</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Poland</country>
      <state>Gdansk</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Poland</country>
      <state>Gdynia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Poland</country>
      <state>Grodzisk Mazowiecki</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Poland</country>
      <state>Katowice</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Poland</country>
      <state>Poznan</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Poland</country>
      <state>Warszawa</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Poland</country>
      <state>Wroclaw</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Romania</country>
      <state>Bucuresti</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Romania</country>
      <state>Iasi</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Romania</country>
      <state>Tirgu Mures</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Russian Federation</country>
      <state>Kazan</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Russian Federation</country>
      <state>Moscow</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Russian Federation</country>
      <state>Ryazan</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Russian Federation</country>
      <state>Saint-Petersburg</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Russian Federation</country>
      <state>St. Petersburg</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Russian Federation</country>
      <state>Vladimir</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Serbia</country>
      <state>Belgrade</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Serbia</country>
      <state>Niska Banja</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Serbia</country>
      <state>Novi Sad</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Slovakia</country>
      <state>Banskobystricky Kraj</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Slovakia</country>
      <state>Dunajska Streda</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Slovakia</country>
      <state>Partizanske</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Slovakia</country>
      <state>Považská Bystrica</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Slovakia</country>
      <state>Zilina</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>A Coruña</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Vizcaya</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Madrid</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Sevilla</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Taiwan</country>
      <state>Taichung</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Taiwan</country>
      <state>Taipei</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Ukraine</country>
      <state>Chernihiv</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Ukraine</country>
      <state>Kharkiv</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Ukraine</country>
      <state>Kyiv</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Ukraine</country>
      <state>Poltava</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Ukraine</country>
      <state>Ternopil</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Ukraine</country>
      <state>Vinnytsia</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Pfizer</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>This is a Phase 2, multicenter, randomized, double blind, double dummy, placebo and
      active-controlled, parallel group study to assess the efficacy and safety of PF 06650833 at
      Week 12 in subjects with moderate-severe, active, RA who have had an inadequate response to
      MTX. PF-06650833 or matching placebo tablets will be administered orally QD under fasting
      conditions, and tofacitinib or matching tofacitinib placebo tablets will be administered
      orally BID for 12 weeks in a blinded fashion.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT02996500</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Pfizer CT.gov Call Center</name>
      <address>Pfizer</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name>Pfizer CT.gov Call Center</name>
      <address />
      <phone>1-800-718-1021</phone>
      <fax />
      <email>ClinicalTrials.gov_Inquiries@pfizer.com</email>
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>